KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) Shares Outstanding (Weighted Average) (2016 - 2025)

Medpace Holdings (MEDP) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $28.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 6.82% year-over-year to $28.8 million, compared with a TTM value of $28.8 million through Dec 2025, down 6.82%, and an annual FY2025 reading of $28.8 million, down 6.82% over the prior year.
  • Shares Outstanding (Weighted Average) was $28.8 million for Q4 2025 at Medpace Holdings, down from $29.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $35.9 million in Q4 2021 and bottomed at $28.8 million in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $31.6 million, with a median of $31.0 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) decreased 13.44% in 2022, then rose 1.48% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $35.9 million in 2021, then decreased by 9.69% to $32.4 million in 2022, then fell by 5.14% to $30.7 million in 2023, then increased by 0.76% to $31.0 million in 2024, then decreased by 6.82% to $28.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MEDP at $28.8 million in Q4 2025, $29.0 million in Q3 2025, and $29.5 million in Q2 2025.